Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTN-005
- Development stage
- Preclinical
- Lead developer
- Centenaire Biosciences
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Vaccines & Immunotherapeutics, Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Parenteral
01
Overview
CTN-005 is an Fc-engineered monoclonal antibody developed by Centenaire Biosciences. It is designed to target both the epidermal growth factor receptor (EGFR) and c-Met (hepatocyte growth factor receptor), functioning as a dual antagonist and inhibitor of these pathways. The drug’s mechanism includes EGFR antagonism and c-Met inhibition, with additional immunotherapeutic effects such as antibody-dependent cell cytotoxicity and immunostimulation. Its primary indication is for the treatment of non-small cell lung cancer (NSCLC), with potential applications in other neoplasms and respiratory diseases. As of the latest updates, CTN-005 remains in preclinical development[1][2].
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on CTN-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTN-005.